On the face of it this seems pretty good. Blair and team continue to deliver

Quarterly Activities & Appendix 4C September 2024

● Biome records $122k of EBITDA for Q1 (Adjusted for share based payments) ○ Third consecutive quarter of positive EBITDA

• ● Record cash receipts of $3.89m in Q1, up 84% vs PCP
• ● Biome reports record quarterly sales revenue $4.25m, up 12% vs Q4 FY24
• ● Biome maintains gross margin above 60% for Q1
• ● Same-store pharmacy sales for Q1 up 68% vs PCP
• ● Clinically proven cholesterol lowering product, Biome Cholesterol launched
• ● Test market in Canada commenced and strategic distribution deal signed
• ● As at September 30th, the company has a cash balance of $2.67m

Fill Announcement click here

Biome Australia (ASX:BIO) | Webinar with Blair Norfolk | 16/10/24 - Sharewise

Click here

BIO has just released their anticipated plan for the next 3 years "Vision 27" click here

Video presentation click here Once again Blair presents very well. Seems to know his stuff, seems to be across various pharmacy markets worldwide.

At first glance the outlook seems positive, potentially very positive

A few key take aways:

• Increase pharmacy/distribution points in Australia from 5,000 - 8,000 (67% TAM)
• Increase companies global footprint, pushing into Canada and Europe. Funded via existing cash flow.
• New product range to launch in H2 FY25.
• Intellectual Property agreement was completed in FY24 and accompanying project to develop novel biological IP is well underway

The push into the North American region begins:

ASX ANNOUNCEMENT

19 September 2024

• ● Biome executes agreement to distribute Activated Proibotics in Canada with new partner Ecotrend Ecologics
• ● Biome’s Activated Probiotics team presents and exhibits at CHFA Now in Toronto

Full Ann - click here

For what it's worth, Canary Capital brought out the following "Equity research report" last week. Click here

While this may be their effort to pump up the share price, its worth a read.

The report gives some background to the company and the industry. It outlines some key risks the company faces.

Also BIO is compared to Blackmore's, Life-space and Swisse. All of which have been bought out.

I attended the BIO company presentation webinar this morning.

For the recording Click here

Blair Norfolk spoke to this document released late last month: Click here

There were no revelations that I picked up on as he stuck to the script and really worked his way through the previously released document, which is worth a read.

He pushed his consistent lines:

• The company produces 18 quality products.
• Biome works closely with Pharmacists and chemists, the aim is to have these professionals promote and sell.
• Biome aims to maximise margins for pharmacists to incentivise recommending the products. The cut for a pharmacy could be from $13-$28 for a Biome product v a few dollars from most products a pharmacist might sell (that was my understanding).
• BIO have avoided working with "discount" chemists etc and do not intent getting into discounting products in a short term sugar rush, race to the bottom.
• When asked about possible cap raise Blair said this was not on the radar.

When asked if there were any funds investing in the company, Blair said that there were some. However none had exceeded the 5% threshold and therefore did not need to disclose these holdings.

Just before the webinar, the company released an announcement to say that will set a new sales record for Q1 2025.

Blair also added that the company will update the market on their Vision 2027 strategic plan sometime in the next three weeks.

ASX ANNOUNCEMENT

2 September 2024

Q1 FY25 Revenue Guidance

● Biome forecast Q1 FY25 sales revenue to surpass $4.0m

Microbiome health company Biome Australia Limited (ASX: BIO) (‘Biome’ or ‘the company’) is pleased to announce, after a strong start to the September quarter, Q1 sales revenue is expected to surpass $4.0m. This result will lead to a new record quarter for sales revenue after last quarter’s record of $3.8m (Q4 FY24).

ASX ANNOUNCEMENT

29 July 2024

Biome shares revenue target as part of Vision 27 Strategic Plan

● Biome sets revenue target of up to $85m cumulative through the next three years (FY25-FY27)

● Biome exceeded the last three-year cumulative target (FY21-24) by 14% overall ($24m vs $21m)

○ The final year of this plan was exceeded by 30% ($13m vs $10m) 

● Biome’s Vision 27 target of up to $85m represents an over 400% increase on previous three-year target.

https://investorpa.com/announcement-pdf/20240819/24906.pdf

There was talk of this 3 year target being an odd move by Blair. Lets see how it plays out

ASX ANNOUNCEMENT

19 August 2024

Biome’s Clinically Proven Cholesterol Reducing Probiotic Launched:

• ● Biome has launched its new cholesterol lowering probiotic, Biome Cholesterol Probiotic, in both pharmacy and practitioner channels.
• ● A double blind, placebo controlled 12 week trial reduced total cholesterol by 14% and LDL (bad cholesterol) by 15% whilst increasing HDL (good cholesterol) by 7% compared to baseline
• ● Potential for Biome Cholesterol Probiotic to be used as an adjunct alongside statins to support increased efficacy of treatment or to reduce the dosage and side effects of this type of treatment
• ● For people who don’t tolerate statins therapy, Biome Cholesterol Probiotic will provide physicians with an additional therapeutic option to help manage the cholesterol levels of these patients
• ● Cardiovascular diseases are the leading cause of death globally with high total cholesterol, high LDL cholesterol and low HDL cholesterol being major risk factors
• ● More than 4 million Australians are reported to be living with cardiovascular diseases

https://investorpa.com/announcement-pdf/20240819/24969.pdf

Blair Norfolk on Ausbiz today:

"we love to under promise and over deliver"

https://ausbiz.com.au/media/biomes-expanding-ecosystem-?videoId=37065

ASX ANNOUNCEMENT

29 July 2024

Biome shares revenue target as part of Vision 27 Strategic Plan

• ● Biome sets revenue target of up to $85m cumulative through the next three years (FY25-FY27)
• ● Biome exceeded the last three-year cumulative target (FY21-24) by 14% overall ($24m vs $21m)

○ The final year of this plan was exceeded by 30% ($13m vs $10m) ● Biome’s Vision 27 target of up to $85m represents an over 400%

increase on previous three-year target

Microbiome health company Biome Australia Limited (ASX: BIO) (‘Biome’ or ‘the company’) is pleased to announce a revenue target that will be driven by Biome’s Vision 27, three-year strategic plan, due to be released to the market later this quarter.

The cumulative revenue target has been set at a range of $75m to $85m over three years (1 July, 2024 - 30 June, 2027). This represents more than 400% growth over the preceding period’s target of $21m and 350% compared to the actual result of $24m in cumulative sales revenue (FY21-24).

The key focus is to continue to invest for growth while continuing to grow profit.

Biome will share the complete Vision 27 with the market later this quarter, supported by an investor webinar.

BIO appears on The Call on Ausbiz today.

Click here

Michael Wayne and Henry Jennings both gave it what I gather was a quick look over.

Both suggesting that investors take profits at this point, given the run up in SP.